REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 7th, 2011 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Illinois
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January 4, 2011, by and between REGENERX BIOPHARMACEUTICALS, INC., a Delaware corporation, (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKRegenerx Biopharmaceuticals Inc • January 7th, 2011 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, [NAME OF INVESTOR], or its permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) up to ________ shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant to that certain Securities Purchase Agreement between the Company and the Holder dated of even date herewith (the “Purchase Agreement”).
REGENERX BIOPHARMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT JANUARY 5, 2011Securities Purchase Agreement • January 7th, 2011 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 5, 2011, is entered into by and between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Sinaf S.A. (the “Investor”).
PURCHASE AGREEMENTPurchase Agreement • January 7th, 2011 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Illinois
PURCHASE AGREEMENT (the “Agreement”), dated as of January 4, 2011, by and between REGENERX BIOPHARMACEUTICALS, INC., a Delaware corporation, (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
REGENERX BIOPHARMACEUTICALS, INC. OMNIBUS WARRANT AMENDMENT AGREEMENTAgreement • January 7th, 2011 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Omnibus Warrant Amendment Agreement (the “Amendment”) is made effective as of January 5, 2011, by and among RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), Defiante Farmaceutica S.A. (“Defiante”), Taufin International S.A. (“Taufin”), as successor in interest to Inverlochy-Consultadoria e Servicos (S.U.) LDA (“Inverlochy”), and Sinaf S.A. (“Sinaf”), as successor in interest to Chaumiere-Consultadoria e Servicos SDC Unipessoal LDA (“Chaumiere”). Defiante, Taufin and Sinaf are referred to collectively herein as the “Holders”.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 7th, 2011 • Regenerx Biopharmaceuticals Inc • Pharmaceutical preparations • Illinois
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 5, 2011, by and between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation, with headquarters located at 15245 Shady Grove Road, Suite 470, Rockville, Maryland 20850 (the “Company”), and Lincoln Park Capital Fund, LLC, an Illinois limited liability company (the “Buyer”).
